Mirum Pharmaceuticals, Inc.
NASDAQMirum Pharmaceuticals enters the post-earnings window with a sharply upgraded growth story — Q1 sales of $159.9M beat estimates by 7%, and management lifted full-year guidance to $660M–$680M, well above the consensus of $644.9M at the time of release. The revenue beat is the headline. Adjusted EPS came in at -$0.50, short of the -$0.35 estimate, but the Street's reaction to biotech…
Snapshot as of 7 May 2026
Mirum Pharmaceuticals enters the post-earnings window with a sharply upgraded growth story — Q1 sales of $159.9M beat estimates by 7%, and management lifted full-year guidance to $660M–$680M, well above the consensus…
MIRM enters its May 6 Q1 earnings report with a substantial short position and a stock that just broke sharply higher — a combination that makes Thursday's release genuinely consequential for both sides of the…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for MIRM — free to start on ORTEX.
Sign up for free →Open MIRM on ORTEX